Skyscape Web Viewer : Radiation Oncology Question Review : Main Index

View All
Pancreatic cancer
Paranasal sinus anticipated 5-yr LRC and OS effect of orbital involvement neuroendocrine differentiation Ohngren's line and Vidian canal staging system for esthesioneuroblastoma subclinical nodal involvement
PCI
Pediatric gliomas genetic syndrome high-grade histologic subtypes second malignancy, risk of treatment approach
Pediatric leukemia cranial irradiation pediatric ALL and AML prognostic features of ALL prognostic features of AML
Penile cancer median survival rate potential critical pre-radiation anatomic factor preservation rate for a T1-t3 prognostic factor risk factors risk of nodal disease staging T2
Phenytoin Answer 2.105 Question 2.105
Pilocytic astrocytomas histopathologic feature for surgery and radiation in vs nonpilocytic tumors
Pituitary tumors fractionated radiation therapy nonfunctional pituitary adenomas pituitary adenoma-induced acromegaly recommended SRS doses secretory type side effect of external-beam radiation treatment SRS vs radiation therapy treatment modality
PMRT
post-mastectomy radiation therapy (PMRT)
Postoperative radiotherapy altered fractionation indications and evidence postoperative dose
primary CNS lymphoma CHOD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) chemotherapy median survival with radiation methotrexate-based chemotherapy risk factors RPA classification treatment
prophylactic cranial irradiation (PCI) Answer 4.77 Answer 4.78 Answer 4.79 Answer 4.80 Answer 4.81 Answer 4.82 Answer 4.83 Answer 4.84 Answer 4.85 survival rate
Prostate cancer-adjuvant and salvage radiation benefits dose regime used for hormone treatments with median PSA predictors of biochemical outcome sites of recurrence s/p prostatectomy survival rate SWOG trials
Prostate cancer-branchytherapy as monotherapy disease-specific outcomes in dose constraints exclusion criteria half-life of I-125 and Pd-103 outcome between I-125 and Pd-103 PSA rise, significance of with EBRT
Prostate cancer-general AUA scores, role in half-life of prostate specific antigen (PSA) in regional lymph node M-staging for adenocarcinoma of nodal staging prognostic parameters Prostate Cancer Prevention Trial (PCPT) trial prostate specific antigen (PSA), screening of Roach equations, reliability of stage migration of
Prostate cancer-high risk and rogen deprivation, effects of ASCENDE-RT trial bony metastasis in EBRT, outcome with PSA follow-up post radiation radiation therapy testosterone production in normal male
Prostate cancer-low risk biochemical failure risks doses for radiation therapy DVH and dosimetric plan, constraints with Epstein criteria IMRT moderate hypofractionation for on active surveillance Pollack dose escalation phase III study RTOG 0126 support treatment treatment Zietman PROG 95-009 phase III study
Prostate cancer-node-positive and rogen deprivation in and rogen deprivation therapy radiation during radical prostatectomy